Login

SURUNKALI BUYRAK YETISHMOVCHILIGIDA ZAMONAVIY DAVOLASH YONDASHUVLARI

Kuchiyeva
Buxoro Abu Ali ibn Sino nomidagi jamoat salomatligi texnikumi o'qituvchisi
Published июн 30, 2026
##issue.issue## ##issue.vol## 2 ##issue.no## 1 (2026): Journal of Global Scientific Innovations
Pages 17-22
Open Access

Annotatsiya

Ushbu maqolada surunkali buyrak yetishmovchiligi (SBY)ning 
zamonaviy etiopatogenetik jihatlari, erta diagnostika usullari va davolashning 
konservativ hamda zamonaviy substitutsion (gemodializ, peritoneal dializ, buyrak 
transplantatsiyasi) yondashuvlari tahlil qilingan. Tadqiqot davomida 2020–2025
yillar oralig'idagi xalqaro va mahalliy adabiyotlar, shuningdek klinik amaliyot 
ma'lumotlari umumlashtirildi. Natijalar SBYning erta bosqichlarida nefroprotektiv 
terapiya, qandli diabet va arterial gipertenziyani nazorat qilish, hamda 
multidisiplinar yondashuvning kasallik progressiyasini sezilarli darajada 
sekinlashtirishini ko'rsatadi. Maqola amaliyotchi shifokorlar uchun zamonaviy 
davolash algoritmlari bo'yicha amaliy tavsiyalar bilan yakunlanadi. 

Kalit so'zlar: surunkali buyrak yetishmovchiligi, gemodializ, peritoneal dializ, buyrak transplantatsiyasi, nefroprotektiv terapiya, glomerulyar filtratsiya tezligi, qandli diabetik nefropatiya

Maqolani onlayn o'qish

140% Yuklanmoqda...
Maqola matni yuklanmoqda, iltimos kuting...

##submission.citations##

  • 1. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of
  • Chronic Kidney Disease. Kidney International Supplements, 2024.
  • 2. Levin A., Stevens P.E., Bilous R.W. et al. Kidney Disease: Improving Global
  • Outcomes (KDIGO) CKD Work Group. Kidney Int., 2021.
  • 3. Webster A.C., Nagler E.V., Morton R.L., Masson P. Chronic Kidney Disease.
  • The Lancet, 2022.
  • 4. Heerspink H.J.L., Stefansson B.V., Correa-Rotter R. et al. Dapagliflozin in
  • Patients with Chronic Kidney Disease. New England Journal of Medicine, 2021.
  • 5. Tuttle K.R., Agarwal R., Alpers C.E. et al. Molecular mechanisms and therapeutic
  • targets for diabetic kidney disease. Kidney International, 2022.
  • 6. Ortiz A., Wanner C., Gansevoort R. Chronic kidney disease as cardiovascular risk
  • factor in routine clinical practice. European Journal of Preventive Cardiology,
  • 2023.
  • 7. Saidov A.A., Rashidova M.T. O'zbekistonda surunkali buyrak kasalliklarining
  • epidemiologik xususiyatlari. O'zbekiston tibbiyot jurnali, 2023.
  • 8. Каримов Х.Я., Тураев Б.Т. Современные методы диагностики и лечения
  • хронической почечной недостаточности. Вестник врача, 2022.
  • 9. Hou F.F., Xie D., Wang J. et al. Effect of ACE Inhibitors on Progression of
  • Chronic Kidney Disease. Journal of the American Society of Nephrology, 2021.
  • 10. Bikbov B., Purcell C.A., Levey A.S. et al. Global, regional, and national burden
  • of chronic kidney disease. The Lancet, 2020.
  • 11. Vart P., Vaduganathan M., Jongs N. et al. Estimated Lifetime Benefit of SGLT2
  • Inhibitors in Patients With CKD. Clinical Journal of the American Society of
  • Nephrology, 2022.
  • 12. Tonelli M., Wanner C. Lipid management in chronic kidney disease: KDIGO
  • clinical practice guideline. Annals of Internal Medicine, 2021.
  • 13. Abdullaeva D.R. Peritoneal dializning klinik samaradorligi: zamonaviy
  • yondashuvlar. Tibbiyot va sport, 2024.